BR112023027083A2 - Molécula de oligonucleotídeo, composição farmacêutica, kit e uso - Google Patents

Molécula de oligonucleotídeo, composição farmacêutica, kit e uso

Info

Publication number
BR112023027083A2
BR112023027083A2 BR112023027083A BR112023027083A BR112023027083A2 BR 112023027083 A2 BR112023027083 A2 BR 112023027083A2 BR 112023027083 A BR112023027083 A BR 112023027083A BR 112023027083 A BR112023027083 A BR 112023027083A BR 112023027083 A2 BR112023027083 A2 BR 112023027083A2
Authority
BR
Brazil
Prior art keywords
kit
oligonucleotide molecule
pharmaceutical composition
forming
residues
Prior art date
Application number
BR112023027083A
Other languages
English (en)
Inventor
Denisa Bojkova
Jindrich Cinatl
Johannes Kleemann
Katja Steinhorst
Stefan Kippenberger
Veronika König
Original Assignee
Johann Wolfgang Goethe Univ Frankfurt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johann Wolfgang Goethe Univ Frankfurt filed Critical Johann Wolfgang Goethe Univ Frankfurt
Publication of BR112023027083A2 publication Critical patent/BR112023027083A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

molécula de oligonucleotídeo, composição farmacêutica, kit e uso. a invenção refere-se a uma molécula de oligonucleotídeo tendo de 10 a 50 nucleotídeos compreendendo pelo menos uma parte formadora de quarteto g compreendendo 10 a 20 resíduos de nucleotídeos, em que pelo menos 60% dos referidos resíduos formadores de motivo formador de quarteto g são resíduos de guanosina ou desoxiguanosina, e sendo que a molécula inibe o crescimento tumoral e/ou a replicação viral ou bacteriana e/ou exerce efeitos anti-inflamatórios em células de mamíferos.
BR112023027083A 2021-06-24 2022-06-23 Molécula de oligonucleotídeo, composição farmacêutica, kit e uso BR112023027083A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21181596.4A EP4108771A1 (en) 2021-06-24 2021-06-24 G- quadruplex- containing oligonucleotides for preventive and therapeutic treatment
PCT/EP2022/067290 WO2022269013A1 (en) 2021-06-24 2022-06-23 G- quadruplex- containing oligonucleotides for preventive and therapeutic treatment

Publications (1)

Publication Number Publication Date
BR112023027083A2 true BR112023027083A2 (pt) 2024-03-12

Family

ID=76999575

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023027083A BR112023027083A2 (pt) 2021-06-24 2022-06-23 Molécula de oligonucleotídeo, composição farmacêutica, kit e uso

Country Status (10)

Country Link
EP (2) EP4108771A1 (pt)
JP (1) JP2024526189A (pt)
KR (1) KR20240026195A (pt)
CN (1) CN117751188A (pt)
AU (1) AU2022296798A1 (pt)
BR (1) BR112023027083A2 (pt)
CA (1) CA3223754A1 (pt)
IL (1) IL309587A (pt)
MX (1) MX2024000039A (pt)
WO (1) WO2022269013A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
KR20050048539A (ko) * 2001-10-06 2005-05-24 메리얼엘엘씨 ＣｐＧ 제제 및 관련된 방법
DE10361502A1 (de) * 2003-12-23 2005-07-28 Phenion Gmbh & Co. Kg Kosmetische oder pharmazeutische Zubereitungen enthaltend Superstruktur-bildende Nukleinsäure-Sequenzen
EP1802643A1 (en) * 2004-10-19 2007-07-04 Replicor Inc. Antiviral oligonucleotides
US20080096838A1 (en) * 2006-08-08 2008-04-24 Kmiec Eric B Guanosine rich oligonucleotides and methods of inducing apoptosis in tumor cells

Also Published As

Publication number Publication date
AU2022296798A1 (en) 2024-02-01
WO2022269013A1 (en) 2022-12-29
EP4359523A1 (en) 2024-05-01
EP4108771A1 (en) 2022-12-28
CN117751188A (zh) 2024-03-22
MX2024000039A (es) 2024-02-21
CA3223754A1 (en) 2022-12-29
JP2024526189A (ja) 2024-07-17
KR20240026195A (ko) 2024-02-27
IL309587A (en) 2024-02-01

Similar Documents

Publication Publication Date Title
Trowell The lymphocyte
Pugh et al. Sinefungin, a potent inhibitor of virion mRNA (guanine-7-)-methyltransferase, mRNA (nucleoside-2'-)-methyltransferase, and viral multiplication.
BR0009884A (pt) Processos e composições para a inibição da função das sequências de polinucleotìdeos
CA3166153A1 (en) Base editors, compositions, and methods for modifying the mitochondrial genome
HUP0303644A2 (hu) Aldóz-reduktáz inhibitor hatású piridazinon-származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
BR112022008415A2 (pt) Composições e métodos para substituição do dna codificado pelo rna dos alelos
Jones et al. Molecular mimicry of human tRNALys anti-codon domain by HIV-1 RNA genome facilitates tRNA primer annealing
BR9801878A (pt) Iniciadores de amplificação de ácido nucleìco modificado
ATE474937T1 (de) Amplifikation und klonierung einzelner dna- moleküle mittels rolling-circle-amplifikation
Mensa‐Wilmot et al. Transcriptional activation of bacteriophage lambda DNA replication in vitro: regulatory role of histone‐like protein HU of Escherichia coli.
BR112022026321A2 (pt) Análogos de 1'-ciano nucleosídeo e usos dos mesmos
BRPI0514680A (pt) produção de anticorpos anti-amilóide beta
Ralph Double-stranded viral RNA
BRPI0814260B8 (pt) composição compreendendo um polímero de fita única, método compreendendo contatar uma célula com tal polímero e uso de tal polímero
BR112021005777A2 (pt) Produtos e composições
WO2021257987A3 (en) Methods and compositions of rna nanostructures for replication and subgenomic expression by rna-directed rna polymerase
Kaczmarski et al. Lupus autoantigen Ku protein binds HIV-1 TAR RNA in vitro
Holmes et al. Structural requirements for tRNA methylation. Action of Escherichia coli tRNA (guanosine-1) methyltransferase on tRNA (1Leu) structural variants.
BRPI0418304A (pt) peptìdeo sintético, uso do mesmo, composição farmacêutica, seqüência de nucleotìdeos, e, métodos para inibição da transmissão de hiv para uma célula, para inibição da fusão de hiv, e para tratamento de um indivìduo infectado com hiv
BR112023027083A2 (pt) Molécula de oligonucleotídeo, composição farmacêutica, kit e uso
Krakow Cyclic adenosine monophosphate receptor: effect of cyclic AMP analogues on DNA binding and proteolytic inactivation
BR112023021231A2 (pt) Produtos e composições
Carroll et al. Reversal by certain polyanions of an endogenous inhibitor of the vesicular stomatitis virus-associated transcriptase.
Chuang et al. Isolation and characterization of nuclear RNA polymerase II from chicken myeloblastosis cells
BRPI0416870A (pt) composições anticáncer sinergìticas